Full Text View
Tabular View
No Study Results Posted
Related Studies
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
This study has been terminated.
Study NCT00092287   Information provided by Ipsen
First Received: September 22, 2004   Last Updated: February 25, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Malignant Carcinoid Syndrome
Additional conditions recognized in this trial
Carcinoid Tumor
Serotonin Syndrome
Syndrome
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Disease
Disorders of Environmental Origin
Drug Toxicity
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Pathologic Processes
Poisoning
Additional drug interventions recognized in this trial
Angiopeptin
Lanreotide
Octreotide
Somatostatin
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Cardiovascular Agents
Gastrointestinal Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Ipsen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services